Celularity Inc
CELUW0.024USD
0.000
Close 11/07, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Celularity Inc Company
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Celularity Inc Info
Ticker SymbolCELUW
Company nameCelularity Inc
IPO dateMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address170 Park Ave
CityFLORHAM PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07932
Phone19087682170
Websitehttps://celularity.com/
Ticker SymbolCELUW
IPO dateMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Company Executives of Celularity Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Nov 7
Updated: Fri, Nov 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
26
2.38M
0.00%
-1.78M
2025Q2
27
2.48M
0.00%
-1.91M
2025Q1
31
2.48M
0.00%
-2.12M
2024Q4
30
2.60M
0.00%
-2.17M
2024Q3
31
2.80M
0.00%
-1.78M
2024Q2
32
2.67M
0.00%
-2.18M
2024Q1
32
2.68M
0.00%
-2.18M
2023Q4
31
3.99M
0.00%
-892.77K
2023Q3
31
4.57M
0.00%
-1.21M
2023Q2
29
5.51M
0.00%
-1.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Walleye Capital LLC
850.11K
0%
--
--
Jun 30, 2025
Linden Advisors L.P.
550.12K
0%
--
--
Jun 30, 2025
Healthcare Of Ontario Pension Plan
350.00K
0%
--
--
Jun 30, 2025
Peak6 Capital Management LLC
171.36K
0%
--
--
Jun 30, 2025
Davidson Kempner Capital Management LP
150.80K
0%
--
--
Jun 30, 2025
Context Capital Management LLC
150.00K
0%
--
--
Jun 30, 2025
Corient Private Wealth LLC
55.00K
0%
--
--
Jun 30, 2025
EMFO, LLC
50.00K
0%
--
--
Jun 30, 2024
Clear Street LLC
11.91K
0%
--
--
Jun 30, 2025
Weaver Capital Management LLC
11.31K
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
